

Contents

Phase I Clinical Trials: Overcoming Barriers Susan E. Bates	1709
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics Patricia M. LoRusso, Scott A. Boerner, and Lesley Seymour	1710
Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer Adrian M. Senderowicz	1719
Approaches to Phase I Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee S. Percy Ivy, Lillian L. Siu, Elizabeth Garrett-Mayer, and Larry Rubinstein	1726
Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan Martin D. Forster, Nagahiro Saijo, Lesley Seymour, and Hilary Calvert	1737
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents Janet E. Dancey, Kevin K. Dobbin, Susan Groshen, J. Milburn Jessup, Andrew H. Hruszkewycz, Maria Koehler, Ralph Parchment, Mark J. Ratain, Lalitha K. Shankar, Walter M. Stadler, Lawrence D. True, Amy Gravell, Michael R. Grever, and On behalf of the Biomarkers Task Force of the NCI Investigational Drug Steering Committee	1745
GCP Data Quality for Early Clinical Development Edwin P. Rock, Vernetta J. Molloy, and Jeffrey S. Humphrey	1756
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee Lesley Seymour, S. Percy Ivy, Daniel Sargent, David Spriggs, Laurence Baker, Larry Rubinstein, Mark J. Ratain, Michael Le Blanc, David Stewart, John Crowley, Susan Groshen, Jeffrey S. Humphrey, Pamela West, and Donald Berry	1764

From the editor

Phase I Clinical Trials: Overcoming Barriers

A medical student, upon hearing an explanation of a Phase I clinical trial, remarked that the first patients to enroll in first-in-human Phase I trials were, in effect, “jumping on the grenade” for those who would come later. There are more drugs in development for cancer indications than ever before – 861 according to PhRMA, yet our ability to carry out Phase I trials is increasingly constrained. This issue of CCR Focus is dedicated to those patients who, for every drug currently on the market, have jumped on the grenade. Multiple factors have coalesced to increase barriers to effectively testing all of these agents. The need for extensive preclinical testing, outlined by Senderowicz, is the first daunting task. Next, the nature of the Phase I trial itself – and concerns about sub-therapeutic dosing – leads patients and their oncologists to delay enrollment in Phase I trials. Exacerbating this, as detailed by Ivy and coauthors, the community has failed to embrace novel, more efficient trial designs that might get to effective doses faster, in favor of the traditional 3 + 3 cohort design. Further, we are victims of our own success: in bringing new therapies to market we have increased the number of salvage options, again reducing enrollment in clinical trials. The complexities of selecting patient populations who are most likely to benefit from a new agent – personalized medicine – also limits our ability to execute Phase I studies effectively. Dancey and colleagues provide some guidance in this area. To help in the steadily growing regulatory burden for data collection and reporting, Rock and colleagues have outlined critical data collection components, providing in essence a GCP primer for the academic oncologist. Of course these issues are not unique to drug development in the United States, as well documented in Calvert’s European/Asian perspective. We have the pipeline. What we don’t have are fast, straightforward methods of getting the drugs through the Critical Path to market and also personalizing what novel drug is best suited for a specific patient. In the following pages, Guest Editors LoRusso and Seymour have brought forward an important collection of papers. Along with guidelines generated by the NCI Investigational Drug Steering Committee’s working groups to improve and speed both Phase I and II trials, they offer the researchers’ own insights into, and ways of managing, the obstacles that impede our progress in this area that is so critical to our collective enterprise. As always, we hope that this issue of *CCR Focus* will challenge those expert in the field and prove valuable to the interested non-expert.

Susan E. Bates, M.D.
Deputy Editor
CCR Focus

Published OnlineFirst 03/09/2010.
doi: 10.1158/1078-0432.CCR-10-0261
©2010 American Association for Cancer Research

Clinical Cancer Research

Phase I Clinical Trials: Overcoming Barriers

Susan E. Bates

Clin Cancer Res 2010;16:1709. Published OnlineFirst March 9, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-10-0261](https://doi.org/10.1158/1078-0432.CCR-10-0261)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/6/1709>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.